HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use HUMALOG safely and effectively. See full prescribing information for HUMALOG.

Humalog (insulin lispro injection, USP [rDNA origin]) for injection
Initial U.S. Approval: 1996

RECENT MAJOR CHANGES

Warnings and Precautions:
Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 mL Cartridges, or Syringe Between Patients (5.1) 02/2015

INDICATIONS AND USAGE
HUMALOG® is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. (1)

DOSAGE AND ADMINISTRATION

The dosage of HUMALOG must be individualized. (2.1)

<table>
<thead>
<tr>
<th>Subcutaneous Injection</th>
<th>Administer within 15 minutes before a meal or immediately after a meal. Use in a regimen with an intermediate- or long-acting insulin. (2.2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Continuous Subcutaneous Infusion Pump</td>
<td>Change the HUMALOG in the reservoir at least every 7 days, change the infusion set, and the infusion set insertion site at least every 3 days. HUMALOG must not be mixed or diluted when used in an external insulin infusion pump. (2.3)</td>
</tr>
<tr>
<td>Intravenous Administration</td>
<td>HUMALOG should be used at concentrations from 0.1 unit/mL to 1 unit/mL in infusion systems containing 0.9% sodium chloride (2.4)</td>
</tr>
</tbody>
</table>

DOSEAGE FORMS AND STRENGTHS

HUMALOG 100 units/mL (U-100) is available as: (3)
- 10 mL vials
- 3 mL vials
- 3 mL Humalog KwikPen® (prefilled)
- 3 mL cartridges

CONTRAINDICATIONS

- Do not use during episodes of hypoglycemia. (4)
- Do not use in patients with hypersensitivity to HUMALOG or any of its excipients. (4)

WARNINGS AND PRECAUTIONS

- Never share a Humalog KwikPen, cartridge, reusable pen compatible with Lilly 3 mL cartridges¹, or syringe between patients, even if the needle is changed. (5.1)
- Dose adjustment and monitoring: Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously and only under medical supervision. (5.2)
- Hypoglycemia: Most common adverse reaction of insulin therapy and may be life-threatening. (5.3)
- Allergic reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with any insulin, including HUMALOG. (5.4)
- Hypokalemia: All insulins, including HUMALOG can cause hypokalemia, which if untreated, may result in respiratory paralysis, ventricular arrhythmia, and death. (5.5)
- Renal or hepatic impairment: Like all insulins, may require a reduction in the HUMALOG dose. (5.6)
- Mixing: HUMALOG for subcutaneous injection should not be mixed with insulins other than NPH insulin. Do not mix HUMALOG with any insulin for use in a continuous infusion pump. (5.7)
- Pump use: Select a new infusion site at least every 3 days and replace the HUMALOG in the pump reservoir at least every 7 days. (5.8)
- Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including HUMALOG. (5.10)

ADVERSE REACTIONS
Adverse reactions associated with HUMALOG include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

- Certain drugs may affect glucose metabolism and may necessitate insulin dose adjustment. (7)
- The signs of hypoglycemia may be reduced or absent in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine). (7)

USE IN SPECIFIC POPULATIONS

Pediatrics: Not studied in children with type 2 diabetes or in children with type 1 diabetes <3 years of age. (8.4)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling. Revised: 3/2015
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology

14 CLINICAL STUDIES
14.1 Type 1 Diabetes – Adults and Adolescents
14.2 Type 2 Diabetes – Adults
14.3 Type 1 Diabetes – Pediatric and Adolescents
14.4 Type 1 Diabetes – Adults Continuous Subcutaneous Insulin Infusion
14.5 Type 1 Diabetes – Pediatric Continuous Subcutaneous Insulin Infusion

16 HOW SUPPLIED/STORAGE AND HANDLING
16.1 How Supplied
16.2 Storage and Handling
16.3 Preparation and Handling
16.4 Admixture for Intravenous Administration

17 PATIENT COUNSELING INFORMATION
17.1 Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 mL Cartridges, or Syringe Between Patients
17.2 Instructions for All Patients
17.3 For Patients Using Continuous Subcutaneous Insulin Pumps

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE
HUMALOG is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

2 DOSAGE AND ADMINISTRATION

2.1 Dosage Considerations
When given subcutaneously, HUMALOG has a more rapid onset of action and a shorter duration of action than regular human insulin.

The dosage of HUMALOG must be individualized. Blood glucose monitoring is essential in all patients receiving insulin therapy.

The total daily insulin requirement may vary and is usually between 0.5 to 1 unit/kg/day. Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

2.2 Subcutaneous Administration
HUMALOG should be given within 15 minutes before a meal or immediately after a meal.

HUMALOG given by subcutaneous injection should generally be used in regimens with an intermediate- or long-acting insulin.

HUMALOG administered by subcutaneous injection should be given in the abdominal wall, thigh, upper arm, or buttocks. Injection sites should be rotated within the same region (abdomen, thigh, upper arm, or buttocks) from one injection to the next to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)].
2.3 Continuous Subcutaneous Infusion (Insulin Pump)

HUMALOG may be administered by continuous subcutaneous infusion by an external insulin pump. Do not use diluted or mixed insulins in external insulin pumps. Infusion sites should be rotated within the same region to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)]. Change the HUMALOG in the reservoir at least every 7 days, change the infusion sets and the infusion set insertion site at least every 3 days.

The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen. Although there is significant variability among patients, approximately 50% of the total dose is usually given as meal-related boluses of HUMALOG and the remainder is given as a basal infusion. HUMALOG is recommended for use in pump systems suitable for insulin infusion such as MiniMed, Disetronic, and other equivalent pumps [see For Patients Using Continuous Subcutaneous Insulin Pumps (17.3)].

2.4 Intravenous Administration

HUMALOG can be administered intravenously under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia [see Warnings and Precautions (5.3, 5.5), How Supplied/Storage and Handling (16.4)]. HUMALOG should be used at concentrations from 0.1 unit/mL to 1.0 unit/mL in infusion systems containing 0.9% sodium chloride.

3 DOSAGE FORMS AND STRENGTHS

HUMALOG 100 units per mL (U-100) is available as:
- 10 mL vials
- 3 mL vials
- 3 mL Humalog KwikPen (prefilled)
- 3 mL cartridges

4 CONTRAINDICATIONS

HUMALOG is contraindicated:
- during episodes of hypoglycemia
- in patients who are hypersensitive to HUMALOG or to any of its excipients.

5 WARNINGS AND PRECAUTIONS

5.1 Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 mL Cartridges, or Syringe Between Patients

Humalog KwikPens, cartridges, and reusable pens compatible with Lilly 3 mL cartridges must never be shared between patients, even if the needle is changed. Patients using Humalog vials must never share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

5.2 Dose Adjustment and Monitoring

Glucose monitoring is essential for patients receiving insulin therapy. Changes to an insulin regimen should be made cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose. Concomitant oral antidiabetic treatment may need to be adjusted.

As with all insulin preparations, the time course of action for HUMALOG may vary in different individuals or at different times in the same individual and is dependent on many conditions, including the
site of injection, local blood supply, or local temperature. Patients who change their level of physical activity or meal plan may require adjustment of insulin dosages.

5.3 Hypoglycemia

Hypoglycemia is the most common adverse effect associated with insulins, including HUMALOG. The risk of hypoglycemia increases with tighter glycemic control. Patients must be educated to recognize and manage hypoglycemia. Hypoglycemia can happen suddenly and symptoms may be different for each person and may change from time to time. Severe hypoglycemia can cause seizures and may be life-threatening or cause death.

The timing of hypoglycemia usually reflects the time-action profile of the administered insulin formulations. Other factors such as changes in food intake (e.g., amount of food or timing of meals), injection site, exercise, and concomitant medications may also alter the risk of hypoglycemia [see Drug Interactions (7)].

As with all insulins, use caution in patients with hypoglycemia unawareness and in patients who may be predisposed to hypoglycemia (e.g., the pediatric population and patients who fast or have erratic food intake). The patient's ability to concentrate and react may be impaired as a result of hypoglycemia. This may present a risk in situations where these abilities are especially important, such as driving or operating other machinery.

Rapid changes in serum glucose levels may induce symptoms similar to hypoglycemia in persons with diabetes, regardless of the glucose value. Early warning symptoms of hypoglycemia may be different or less pronounced under certain conditions, such as longstanding diabetes, diabetic nerve disease, use of medications such as beta-blockers [see Drug Interactions (7)], or intensified diabetes control. These situations may result in severe hypoglycemia (and, possibly, loss of consciousness) prior to the patient's awareness of hypoglycemia.

5.4 Hypersensitivity and Allergic Reactions

Severe, life-threatening, generalized allergy, including anaphylaxis, can occur with insulin products, including HUMALOG [see Adverse Reactions (6.1)].

5.5 Hypokalemia

All insulin products, including HUMALOG, cause a shift in potassium from the extracellular to intracellular space, possibly leading to hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Use caution in patients who may be at risk for hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations and patients receiving intravenously administered insulin).

5.6 Renal or Hepatic Impairment

Frequent glucose monitoring and insulin dose reduction may be required in patients with renal or hepatic impairment [see Clinical Pharmacology (12.3)].

5.7 Mixing of Insulins

HUMALOG for subcutaneous injection should not be mixed with insulin preparations other than NPH insulin. If HUMALOG is mixed with NPH insulin, HUMALOG should be drawn into the syringe first. Injection should occur immediately after mixing.

Do not mix HUMALOG with other insulins for use in an external subcutaneous infusion pump.

5.8 Subcutaneous Insulin Infusion Pumps

When used in an external insulin pump for subcutaneous infusion, HUMALOG should not be diluted or mixed with any other insulin. Change the HUMALOG in the reservoir at least every 7 days, change the
infusion sets and the infusion set insertion site at least every 3 days. HUMALOG should not be exposed to temperatures greater than 98.6°F (37°C).

Malfunction of the insulin pump or infusion set or insulin degradation can rapidly lead to hyperglycemia and ketosis. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Interim subcutaneous injections with HUMALOG may be required. Patients using continuous subcutaneous insulin infusion pump therapy must be trained to administer insulin by injection and have alternate insulin therapy available in case of pump failure [see Dosage and Administration (2.3), How Supplied/Storage and Handling (16), and Patient Counseling Information (17.3)].

5.9 Drug Interactions

Some medications may alter insulin requirements and the risk for hypoglycemia or hyperglycemia [see Drug Interactions (7)].

5.10 Fluid Retention and Heart Failure with Concomitant Use of PPAR-gamma Agonists

Thiazolidinediones (TZDs), which are peroxisome proliferator-activated receptor (PPAR)-gamma agonists, can cause dose-related fluid retention, particularly when used in combination with insulin. Fluid retention may lead to or exacerbate heart failure. Patients treated with insulin, including HUMALOG, and a PPAR-gamma agonist should be observed for signs and symptoms of heart failure. If heart failure develops, it should be managed according to current standards of care, and discontinuation or dose reduction of the PPAR-gamma agonist must be considered.

6 ADVERSE REACTIONS

The following adverse reactions are discussed elsewhere:

- Hypoglycemia [see Warnings and Precautions (5.3)].
- Hypokalemia [see Warnings and Precautions (5.5)].

6.1 Clinical Trial Experience

Because clinical trials are conducted under widely varying designs, the adverse reaction rates reported in one clinical trial may not be easily compared with those rates reported in another clinical trial, and may not reflect the rates actually observed in clinical practice.

The frequencies of Treatment-Emergent Adverse Events during HUMALOG clinical trials in patients with type 1 diabetes mellitus and type 2 diabetes mellitus are listed in the tables below.

Table 1: Treatment-Emergent Adverse Events in Patients with Type 1 Diabetes Mellitus (adverse events with frequency ≥5%)

<table>
<thead>
<tr>
<th>Events, n (%)</th>
<th>Lispro (n=81)</th>
<th>Regular human insulin (n=86)</th>
<th>Total (n=167)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flu syndrome</td>
<td>28 (34.6)</td>
<td>28 (32.6)</td>
<td>56 (33.5)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>27 (33.3)</td>
<td>29 (33.7)</td>
<td>56 (33.5)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>20 (24.7)</td>
<td>25 (29.1)</td>
<td>45 (26.9)</td>
</tr>
<tr>
<td>Headache</td>
<td>24 (29.6)</td>
<td>19 (22.1)</td>
<td>43 (25.7)</td>
</tr>
<tr>
<td>Pain</td>
<td>16 (19.8)</td>
<td>14 (16.3)</td>
<td>30 (18.0)</td>
</tr>
<tr>
<td>Cough increased</td>
<td>14 (17.3)</td>
<td>15 (17.4)</td>
<td>29 (17.4)</td>
</tr>
<tr>
<td>Infection</td>
<td>11 (13.6)</td>
<td>18 (20.9)</td>
<td>29 (17.4)</td>
</tr>
<tr>
<td>Nausea</td>
<td>5 (6.2)</td>
<td>13 (15.1)</td>
<td>18 (10.8)</td>
</tr>
<tr>
<td>Accidental injury</td>
<td>7 (8.6)</td>
<td>10 (11.6)</td>
<td>17 (10.2)</td>
</tr>
<tr>
<td>Surgical procedure</td>
<td>5 (6.2)</td>
<td>12 (14.0)</td>
<td>17 (10.2)</td>
</tr>
<tr>
<td>Fever</td>
<td>5 (6.2)</td>
<td>10 (11.6)</td>
<td>15 (9.0)</td>
</tr>
</tbody>
</table>
Abdominal pain | 6 (7.4) | 7 (8.1) | 13 (7.8)
Asthenia | 6 (7.4) | 7 (8.1) | 13 (7.8)
Bronchitis | 6 (7.4) | 6 (7.0) | 12 (7.2)
Diarrhea | 7 (8.6) | 5 (5.8) | 12 (7.2)
Dysmenorrhea | 5 (6.2) | 6 (7.0) | 11 (6.6)
Myalgia | 6 (7.4) | 5 (5.8) | 11 (6.6)
Urinary tract infection | 5 (6.2) | 4 (4.7) | 9 (5.4)

Table 2: Treatment-Emergent Adverse Events in Patients with Type 2 Diabetes Mellitus (adverse events with frequency ≥5%)

<table>
<thead>
<tr>
<th>Events, n (%)</th>
<th>Lispro (n=714)</th>
<th>Regular human insulin (n=709)</th>
<th>Total (n=1423)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>63 (11.6)</td>
<td>66 (9.3)</td>
<td>149 (10.5)</td>
</tr>
<tr>
<td>Pain</td>
<td>77 (10.8)</td>
<td>71 (10.0)</td>
<td>148 (10.4)</td>
</tr>
<tr>
<td>Infection</td>
<td>72 (10.1)</td>
<td>54 (7.6)</td>
<td>126 (8.9)</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>47 (6.6)</td>
<td>58 (8.2)</td>
<td>105 (7.4)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>58 (8.1)</td>
<td>47 (6.6)</td>
<td>105 (7.4)</td>
</tr>
<tr>
<td>Flu syndrome</td>
<td>44 (6.2)</td>
<td>58 (8.2)</td>
<td>102 (7.2)</td>
</tr>
<tr>
<td>Surgical procedure</td>
<td>53 (7.4)</td>
<td>48 (6.8)</td>
<td>101 (7.1)</td>
</tr>
</tbody>
</table>

Insulin initiation and intensification of glucose control

Intensification or rapid improvement in glucose control has been associated with a transitory, reversible ophthalmologic refraction disorder, worsening of diabetic retinopathy, and acute painful peripheral neuropathy. However, long-term glycemic control decreases the risk of diabetic retinopathy and neuropathy.

Lipodystrophy

Long-term use of insulin, including HUMALOG, can cause lipodystrophy at the site of repeated insulin injections or infusion. Lipodystrophy includes lipohypertrophy (thickening of adipose tissue) and lipoatrophy (thinning of adipose tissue), and may affect insulin absorption. Rotate insulin injection or infusion sites within the same region to reduce the risk of lipodystrophy [see Dosage and Administration (2.2, 2.3)].

Weight gain

Weight gain can occur with insulin therapy, including HUMALOG, and has been attributed to the anabolic effects of insulin and the decrease in glucosuria.

Peripheral Edema

Insulin, including HUMALOG, may cause sodium retention and edema, particularly if previously poor metabolic control is improved by intensified insulin therapy.

Adverse Reactions with Continuous Subcutaneous Insulin Infusion (CSII)

In a 12-week, randomized, crossover study in adult patients with type 1 diabetes (n=39), the rates of catheter occlusions and infusion site reactions were similar for HUMALOG and regular human insulin treated patients (see Table 3).

Table 3: Catheter Occlusions and Infusion Site Reactions

<table>
<thead>
<tr>
<th>HUMALOG (n=38)</th>
<th>Regular human insulin (n=39)</th>
<th>Total (n=78)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Occlusions</td>
<td>5 (6.4)</td>
<td>4 (4.9)</td>
</tr>
<tr>
<td>Site reactions</td>
<td>7 (8.0)</td>
<td>6 (6.9)</td>
</tr>
</tbody>
</table>
In a randomized, 16-week, open-label, parallel design study of children and adolescents with type 1 diabetes, adverse event reports related to infusion-site reactions were similar for insulin lispro and insulin aspart (21% of 100 patients versus 17% of 198 patients, respectively). In both groups, the most frequently reported infusion site adverse events were infusion site erythema and infusion site reaction.

**Allergic Reactions**

*Local Allergy* — As with any insulin therapy, patients taking HUMALOG may experience redness, swelling, or itching at the site of the injection. These minor reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation of HUMALOG. In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique.

*Systemic Allergy* — Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with any insulin, including HUMALOG. Generalized allergy to insulin may cause whole body rash (including pruritus), dyspnea, wheezing, hypotension, tachycardia, or diaphoresis.

In controlled clinical trials, pruritus (with or without rash) was seen in 17 patients receiving regular human insulin (n=2969) and 30 patients receiving HUMALOG (n=2944).

Localized reactions and generalized myalgias have been reported with injected metacresol, which is an excipient in HUMALOG [see Contraindications (4)].

**Antibody Production**

In large clinical trials with patients with type 1 (n=509) and type 2 (n=262) diabetes mellitus, anti-insulin antibody (insulin lispro-specific antibodies, insulin-specific antibodies, cross-reactive antibodies) formation was evaluated in patients receiving both regular human insulin and HUMALOG (including patients previously treated with human insulin and naïve patients). As expected, the largest increase in the antibody levels occurred in patients new to insulin therapy. The antibody levels peaked by 12 months and declined over the remaining years of the study. These antibodies do not appear to cause deterioration in glycemic control or necessitate an increase in insulin dose. There was no statistically significant relationship between the change in the total daily insulin dose and the change in percent antibody binding for any of the antibody types.

### 6.2 Postmarketing Experience

The following additional adverse reactions have been identified during post-approval use of HUMALOG. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Medication errors in which other insulins have been accidentally substituted for HUMALOG have been identified during postapproval use [see Patient Counseling Information (17.2)].

### 7 DRUG INTERACTIONS

A number of drugs affect glucose metabolism and may require insulin dose adjustment and particularly close monitoring.

Following are some of the examples:

- **Drugs That May Increase the Blood-Glucose-Lowering Effect of HUMALOG and Susceptibility to Hypoglycemia:** Oral antidiabetic agents, salicylates, sulfonamide antibiotics, monoamine oxidase inhibitors, fluoxetine, pramlintide, disopyramide, fibrates, propoxyphene, pentoxifylline, ACE inhibitors, angiotensin II receptor blocking agents, and somatostatin analogs
Drugs That May Reduce the Blood-Glucose-Lowering Effect of HUMALOG: corticosteroids, isoniazid, niacin, estrogens, oral contraceptives, phenothiazines, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, albuterol, terbutaline), somatropin, atypical antipsychotics, glucagon, protease inhibitors, and thyroid hormones.

Drugs That May Increase or Reduce the Blood-Glucose-Lowering Effect of HUMALOG: beta-blockers, clonidine, lithium salts, and alcohol. Pentamidine may cause hypoglycemia, which may sometimes be followed by hyperglycemia.

Drugs That May Reduce the Signs of Hypoglycemia: beta-blockers, clonidine, guanethidine, and reserpine.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Category B. All pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. This background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. It is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. In patients with diabetes or gestational diabetes insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly decline after delivery. Careful monitoring of glucose control is essential in these patients. Therefore, female patients should be advised to tell their physicians if they intend to become, or if they become pregnant while taking HUMALOG.

Although there are limited clinical studies of the use of HUMALOG in pregnancy, published studies with human insulins suggest that optimizing overall glycemic control, including postprandial control, before conception and during pregnancy improves fetal outcome.

In a combined fertility and embryo-fetal development study, female rats were given subcutaneous insulin lispro injections of 5 and 20 units/kg/day (0.8 and 3 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area, respectively) from 2 weeks prior to cohabitation through Gestation Day 19. There were no adverse effects on female fertility, implantation, or fetal viability and morphology. However, fetal growth retardation was produced at the 20 units/kg/day-dose as indicated by decreased fetal weight and an increased incidence of fetal runts/litter.

In an embryo-fetal development study in pregnant rabbits, insulin lispro doses of 0.1, 0.25, and 0.75 unit/kg/day (0.03, 0.08, and 0.24 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area, respectively) were injected subcutaneously on Gestation days 7 through 19. There were no adverse effects on fetal viability, weight, and morphology at any dose.

8.3 Nursing Mothers

It is unknown whether insulin lispro is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when HUMALOG is administered to a nursing woman. Use of HUMALOG is compatible with breastfeeding, but women with diabetes who are lactating may require adjustments of their insulin doses.

8.4 Pediatric Use

HUMALOG is approved for use in children for subcutaneous daily injections and for subcutaneous continuous infusion by external insulin pump. HUMALOG has not been studied in pediatric patients younger than 3 years of age. HUMALOG has not been studied in pediatric patients with type 2 diabetes [see Clinical Studies (14)].

As in adults, the dosage of HUMALOG must be individualized in pediatric patients based on metabolic
needs and results of frequent monitoring of blood glucose.

8.5 Geriatric Use

Of the total number of subjects (n=2834) in eight clinical studies of HUMALOG, twelve percent (n=338) were 65 years of age or over. The majority of these had type 2 diabetes. HbA1c values and hypoglycemia rates did not differ by age. Pharmacokinetic/pharmacodynamic studies to assess the effect of age on the onset of HUMALOG action have not been performed.

10 OVERDOSAGE

Excess insulin administration may cause hypoglycemia and hypokalemia. Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.

11 DESCRIPTION

HUMALOG® (insulin lispro injection, USP [rDNA origin]) is a rapid-acting human insulin analog used to lower blood glucose. Insulin lispro is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli. Insulin lispro differs from human insulin in that the amino acid proline at position B28 is replaced by lysine and the lysine in position B29 is replaced by proline. Chemically, it is Lys(B28), Pro(B29) human insulin analog and has the empirical formula C_{257}H_{383}N_{65}O_{77}S_{6} and a molecular weight of 5808, both identical to that of human insulin.

HUMALOG has the following primary structure:

![HUMALOG primary structure diagram]

HUMALOG is a sterile, aqueous, clear, and colorless solution. Each milliliter of HUMALOG contains insulin lispro 100 units, 16 mg glycerin, 1.88 mg dibasic sodium phosphate, 3.15 mg Metacresol, zinc oxide content adjusted to provide 0.0197 mg zinc ion, trace amounts of phenol, and Water for Injection. Insulin lispro has a pH of 7.0 to 7.8. The pH is adjusted by addition of aqueous solutions of hydrochloric acid 10% and/or sodium hydroxide 10%.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.
12.2 Pharmacodynamics

HUMALOG has been shown to be equipotent to human insulin on a molar basis. One unit of HUMALOG has the same glucose-lowering effect as one unit of regular human insulin. Studies in normal volunteers and patients with diabetes demonstrated that HUMALOG has a more rapid onset of action and a shorter duration of activity than regular human insulin when given subcutaneously.

The time course of action of insulin and insulin analogs, such as HUMALOG, may vary considerably in different individuals or within the same individual. The parameters of HUMALOG activity (time of onset, peak time, and duration) as designated in Figure 1 should be considered only as general guidelines. The rate of insulin absorption, and consequently the onset of activity are known to be affected by the site of injection, exercise, and other variables [see Warnings and Precautions (5.2)].

![Figure 1: Blood Glucose Levels After Subcutaneous Injection of Regular Human Insulin or HUMALOG (0.2 unit/kg) Immediately Before a High Carbohydrate Meal in 10 Patients with Type 1 Diabetes.]

Baseline insulin concentration was maintained by infusion of 0.2 mU/min/kg human insulin.

**Intravenous Administration of HUMALOG** — The glucose lowering effect of intravenously administered HUMALOG was tested in 21 patients with type 1 diabetes. For the study, the patients' usual doses of insulin were held and blood glucose concentrations were allowed to reach a stable range of 200 to 260 mg/dL during a one to three hours run-in phase. The run-in phase was followed by a 6-hour assessment phase. During the assessment phase, patients received intravenous HUMALOG at an initial infusion rate of 0.5 units/hour. The infusion rate of HUMALOG could be adjusted at regular timed intervals to achieve and maintain blood glucose concentrations between 100 to 160 mg/dL.

The mean blood glucose levels during the assessment phase for patients on HUMALOG therapy are summarized below in Table 4. All patients achieved the targeted glucose range at some point during the 6-hour assessment phase. At the endpoint, blood glucose was within the target range (100 to 160 mg/dL) for 17 of 20 patients treated with HUMALOG. The average time (±SE) required to attain near normoglycemia was 129 ± 14 minutes for HUMALOG.

**Table 4: Mean Blood Glucose Concentrations (mg/dL) During Intravenous Infusions of HUMALOG**
<table>
<thead>
<tr>
<th>Time from Start of Infusion (minutes)</th>
<th>Mean Blood Glucose (mg/dL) Intravenous&lt;sup&gt;a&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>224 ± 16</td>
</tr>
<tr>
<td>30</td>
<td>205 ± 21</td>
</tr>
<tr>
<td>60</td>
<td>195 ± 20</td>
</tr>
<tr>
<td>120</td>
<td>165 ± 26</td>
</tr>
<tr>
<td>180</td>
<td>140 ± 26</td>
</tr>
<tr>
<td>240</td>
<td>123 ± 20</td>
</tr>
<tr>
<td>300</td>
<td>120 ± 27</td>
</tr>
<tr>
<td>360</td>
<td>122 ± 25</td>
</tr>
</tbody>
</table>

<sup>a</sup> Results shown as mean ± SD

12.3 Pharmacokinetics

Absorption and Bioavailability — Studies in healthy volunteers and patients with diabetes demonstrated that HUMALOG is absorbed more quickly than regular human insulin. In healthy volunteers given subcutaneous doses of HUMALOG ranging from 0.1 to 0.4 unit/kg, peak serum levels were seen 30 to 90 minutes after dosing. When healthy volunteers received equivalent doses of regular human insulin, peak insulin levels occurred between 50 to 120 minutes after dosing. Similar results were seen in patients with type 1 diabetes (see Figure 2).

![Figure 2: Serum HUMALOG and Insulin Levels After Subcutaneous Injection of Regular Human Insulin or HUMALOG (0.2 unit/kg) Immediately Before a High Carbohydrate Meal in 10 Patients with Type 1 Diabetes.<sup>a</sup>](image)

<sup>a</sup> Baseline insulin concentration was maintained by infusion of 0.2 mU/min/kg human insulin.

HUMALOG was absorbed at a consistently faster rate than regular human insulin in healthy male volunteers given 0.2 unit/kg at abdominal, deltoid, or femoral subcutaneous sites. After HUMALOG was administered in the abdomen, serum drug levels were higher and the duration of action was slightly shorter than after deltoid or thigh administration. Bioavailability of HUMALOG is similar to that of
regular human insulin. The absolute bioavailability after subcutaneous injection ranges from 55% to 77% with doses between 0.1 to 0.2 unit/kg, inclusive.

**Distribution** — When administered intravenously as bolus injections of 0.1 and 0.2 U/kg dose in two separate groups of healthy subjects, the mean volume of distribution of HUMALOG appeared to decrease with increase in dose (1.55 and 0.72 L/kg, respectively) in contrast to that of regular human insulin for which, the volume of distribution was comparable across the two dose groups (1.37 and 1.12 L/kg for 0.1 and 0.2 U/kg dose, respectively).

**Metabolism** — Human metabolism studies have not been conducted. However, animal studies indicate that the metabolism of HUMALOG is identical to that of regular human insulin.

**Elimination** — After subcutaneous administration of HUMALOG, the t\(_{1/2}\) is shorter than that of regular human insulin (1 versus 1.5 hours, respectively). When administered intravenously, HUMALOG and regular human insulin demonstrated similar dose-dependent clearance, with a mean clearance of 21.0 mL/min/kg and 21.4 mL/min/kg, respectively (0.1 unit/kg dose), and 9.6 mL/min/kg and 9.4 mL/min/kg, respectively (0.2 unit/kg dose). Accordingly, HUMALOG demonstrated a mean t\(_{1/2}\) of 0.85 hours (51 minutes) and 0.92 hours (55 minutes), respectively for 0.1 unit/kg and 0.2 unit/kg doses, and regular human insulin mean t\(_{1/2}\) was 0.79 hours (47 minutes) and 1.28 hours (77 minutes), respectively for 0.1 unit/kg and 0.2 unit/kg doses.

**Specific Populations**

**Age** — The effect of age on the pharmacokinetics of HUMALOG has not been studied. However, in large clinical trials, sub-group analysis based on age did not indicate any difference in postprandial glucose parameters between HUMALOG and regular human insulin.

**Gender** — The effect of gender on the pharmacokinetics of HUMALOG has not been studied. However, in large clinical trials, sub-group analysis based on gender did not indicate any difference in postprandial glucose parameters between HUMALOG and regular human insulin.

**Renal Impairment** — Type 2 diabetic patients with varying degree of renal impairment showed no difference in pharmacokinetics of regular insulin and HUMALOG. However, the sensitivity of the patients to insulin did change, with an increased response to insulin as the renal function declined. Some studies with human insulin have shown increased circulating levels of insulin in patients with renal impairment. Careful glucose monitoring and dose adjustments of insulin, including HUMALOG, may be necessary in patients with renal dysfunction [see Warnings and Precautions (5.6)].

**Hepatic Impairment** — Type 2 diabetic patients with impaired hepatic function showed no effect on the pharmacokinetics of HUMALOG as compared to patients with no hepatic dysfunction. However, some studies with human insulin have shown increased circulating levels of insulin in patients with liver failure. Careful glucose monitoring and dose adjustments of insulin, including HUMALOG, may be necessary in patients with hepatic dysfunction.

**Race** — The effects of race on the pharmacokinetics and pharmacodynamics of HUMALOG have not been studied.

**Obesity** — The effect of obesity on the pharmacokinetics and pharmacodynamics of HUMALOG has not been studied.

**Pregnancy** — The effect of pregnancy on the pharmacokinetics and pharmacodynamics of HUMALOG has not been studied [see Use in Specific Populations (8.1)].

**Smoking** — The effect of smoking on the pharmacokinetics and pharmacodynamics of HUMALOG has not been studied.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Standard 2-year carcinogenicity studies in animals have not been performed. In Fischer 344 rats, a 12-month repeat-dose toxicity study was conducted with insulin lispro at subcutaneous doses of 20 and 200 units/kg/day (approximately 3 and 32 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area). Insulin lispro did not produce important target organ toxicity including mammary tumors at any dose.

Insulin lispro was not mutagenic in the following genetic toxicity assays: bacterial mutation, unscheduled DNA synthesis, mouse lymphoma, chromosomal aberration and micronucleus assays.

Male fertility was not compromised when male rats given subcutaneous insulin lispro injections of 5 and 20 units/kg/day (0.8 and 3 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area) for 6 months were mated with untreated female rats. In a combined fertility, perinatal, and postnatal study in male and female rats given 1, 5, and 20 units/kg/day subcutaneously (0.16, 0.8, and 3 times the human subcutaneous dose of 1 unit/kg/day, based on units/body surface area), mating and fertility were not adversely affected in either gender at any dose.

13.2 Animal Toxicology and/or Pharmacology

In standard biological assays in fasted rabbits, 0.2 unit/kg of insulin lispro injected subcutaneously had the same glucose-lowering effect and had a more rapid onset of action as 0.2 unit/kg of regular human insulin.

14 CLINICAL STUDIES

The safety and efficacy of HUMALOG were studied in children, adolescent, and adult patients with type 1 diabetes (n=789) and adult patients with type 2 diabetes (n=722).

14.1 Type 1 Diabetes – Adults and Adolescents

A 12-month, randomized, parallel, open-label, active-controlled study was conducted in patients with type 1 diabetes to assess the safety and efficacy of HUMALOG (n=81) compared with Humulin R [REGULAR insulin human injection, USP (rDNA origin)] (n=86). HUMALOG was administered by subcutaneous injection immediately prior to meals and Humulin R was administered 30 to 45 minutes before meals. Humulin U [ULTRALENTE human insulin (rDNA origin) extended zinc suspension] was administered once or twice daily as the basal insulin. There was a 2- to 4-week run-in period with Humulin R and Humulin U before randomization. Most patients were Caucasian (97%). Forty-seven percent of the patients were male. The mean age was 31 years (range 12 to 70 years). Glycemic control, the total daily doses of HUMALOG and Humulin R, and the incidence of severe hypoglycemia (as determined by the number of events that were not self-treated) were similar in the two treatment groups. There were no episodes of diabetic ketoacidosis in either treatment group.

<table>
<thead>
<tr>
<th>Treatment Duration</th>
<th>12 months HUMALOG</th>
<th>12 months Humulin U</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment in Combination with:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline HbA1c (%)</td>
<td>8.2 ± 1.4</td>
<td>8.3 ± 1.7</td>
</tr>
<tr>
<td>Change from baseline HbA1c (%)</td>
<td>-0.1 ± 0.9</td>
<td>0.1 ± 1.1</td>
</tr>
<tr>
<td>Treatment Difference in HbA1c Mean (95% confidence interval)</td>
<td>0.4 (0.0, 0.8)</td>
<td></td>
</tr>
<tr>
<td>Baseline short-acting insulin dose (units/kg/day)</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
</tr>
<tr>
<td>End-of-Study short-acting insulin dose (units/kg/day)</td>
<td>0.3 ± 0.1</td>
<td>0.3 ± 0.1</td>
</tr>
<tr>
<td>Change from baseline short-acting insulin dose (units/kg/day)</td>
<td>0.0 ± 0.1</td>
<td>0.0 ± 0.1</td>
</tr>
<tr>
<td>Baseline Body weight (kg)</td>
<td>72 ± 12.7</td>
<td>71 ± 11.3</td>
</tr>
</tbody>
</table>
14.2 Type 2 Diabetes – Adults

A 6-month randomized, crossover, open-label, active-controlled study was conducted in insulin-treated patients with type 2 diabetes (n=722) to assess the safety and efficacy of HUMALOG for 3 months followed by Humulin R for 3 months or the reverse sequence. HUMALOG was administered by subcutaneous injection immediately before meals and Humulin R was administered 30 to 45 minutes before meals. Humulin® N [NPH human insulin (rDNA origin) isophane suspension] or Humulin U was administered once or twice daily as the basal insulin. All patients participated in a 2- to 4-week run-in period with Humulin R and Humulin N or Humulin U. Most of the patients were Caucasian (88%), and the numbers of men and women in each group were approximately equal. The mean age was 58.6 years (range 23.8 to 85 years). The average body mass index (BMI) was 28.2 kg/m². During the study, the majority of patients used Humulin N (84%) compared with Humulin U (16%) as their basal insulin. The reductions from baseline in HbA₁c and the incidence of severe hypoglycemia (as determined by the number of events that were not self-treated) were similar between the two treatments from the combined groups (see Table 6).

<table>
<thead>
<tr>
<th>End point</th>
<th>Baseline</th>
<th>HUMALOG + Basal</th>
<th>Humulin R + Basal</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA₁c (%)</td>
<td>8.9 ± 1.7</td>
<td>8.2 ± 1.3</td>
<td>8.2 ± 1.4</td>
</tr>
<tr>
<td>Change from baseline HbA₁c (%)</td>
<td>—</td>
<td>-0.7 ± 1.4</td>
<td>-0.7 ± 1.3</td>
</tr>
<tr>
<td>Short-acting insulin dose (units/kg/day)</td>
<td>0.3 ± 0.2</td>
<td>0.3 ± 0.2</td>
<td>0.3 ± 0.2</td>
</tr>
<tr>
<td>Change from baseline short-acting insulin dose (units/kg/day)</td>
<td>—</td>
<td>0.0 ± 0.1</td>
<td>0.0 ± 0.1</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>80 ± 15</td>
<td>81 ± 15</td>
<td>81 ± 15</td>
</tr>
<tr>
<td>Weight change from baseline</td>
<td>—</td>
<td>0.8 ± 2.7</td>
<td>0.9 ± 2.6</td>
</tr>
<tr>
<td>Patients with severe hypoglycemia (n, %)</td>
<td>—</td>
<td>15 (2%)</td>
<td>16 (2%)</td>
</tr>
</tbody>
</table>

**Table 6: Type 2 Diabetes Mellitus — Adults**

<table>
<thead>
<tr>
<th>End point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
</tr>
<tr>
<td>HUMALOG</td>
</tr>
<tr>
<td>Humulin R</td>
</tr>
</tbody>
</table>

**14.3 Type 1 Diabetes – Pediatric and Adolescents**

An 8-month, crossover study of adolescents with type 1 diabetes (n=463), aged 9 to 19 years, compared two subcutaneous multiple-dose treatment regimens: HUMALOG or Humulin R, both administered with Humulin N (NPH human insulin) as the basal insulin. HUMALOG achieved glycemic control comparable to Humulin R, as measured by HbA₁c (see Table 7), and both treatment groups had a comparable incidence of hypoglycemia. In a 9-month, crossover study of prepubescent children (n=60) with type 1 diabetes, aged 3 to 11 years, HUMALOG administered immediately before meals, HUMALOG administered immediately after meals and Humulin R administered 30 minutes before meals resulted in similar glycemic control, as measured by HbA₁c, and incidence of hypoglycemia, regardless of treatment group.

<table>
<thead>
<tr>
<th>End point</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
</tr>
<tr>
<td>HUMALOG</td>
</tr>
<tr>
<td>Humulin R</td>
</tr>
</tbody>
</table>
**14.4 Type 1 Diabetes – Adults Continuous Subcutaneous Insulin Infusion**

To evaluate the administration of HUMALOG via external insulin pumps, two open-label, crossover design studies were performed in patients with type 1 diabetes. One study involved 39 patients, ages 19 to 58 years, treated for 24 weeks with HUMALOG or regular human insulin. After 12 weeks of treatment, the mean HbA₁c values decreased from 7.8% to 7.2% in the HUMALOG-treated patients and from 7.8% to 7.5% in the regular human insulin-treated patients. Another study involved 60 patients (mean age 39, range 15 to 58 years) treated for 24 weeks with either HUMALOG or buffered regular human insulin. After 12 weeks of treatment, the mean HbA₁c values decreased from 7.7% to 7.4% in the HUMALOG-treated patients and remained unchanged from 7.7% in the buffered regular human insulin-treated patients. Rates of hypoglycemia were comparable between treatment groups in both studies.

**14.5 Type 1 Diabetes – Pediatric Continuous Subcutaneous Insulin Infusion**

A randomized, 16-week, open-label, parallel design, study of children and adolescents with type 1 diabetes (n=298) aged 4 to 18 years compared two subcutaneous infusion regimens administered via an external insulin pump: insulin aspart (n=198) or HUMALOG (n=100). These two treatments resulted in comparable changes from baseline in HbA₁c and comparable rates of hypoglycemia after 16 weeks of treatment (see Table 8). Infusion site reactions were similar between groups.

**Table 8: Pediatric Insulin Pump Study in Type 1 Diabetes (16 weeks; n=298)**

<table>
<thead>
<tr>
<th></th>
<th>HUMALOG</th>
<th>Aspart</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>100</td>
<td>198</td>
</tr>
<tr>
<td>Baseline HbA₁c (%)</td>
<td>8.2 ± 0.8</td>
<td>8.0 ± 0.9</td>
</tr>
<tr>
<td>Change from Baseline HbA₁c (%)</td>
<td>-0.1 ± 0.7</td>
<td>-0.1 ± 0.8</td>
</tr>
<tr>
<td>Treatment Difference in HbA₁c, Mean (95% confidence interval)</td>
<td>0.1 (-0.3, 0.1)</td>
<td></td>
</tr>
<tr>
<td>Baseline insulin dose (units/kg/24 hours)</td>
<td>0.9 ± 0.3</td>
<td>0.9 ± 0.3</td>
</tr>
<tr>
<td>End-of-Study insulin dose (units/kg/24 hours)</td>
<td>0.9 ± 0.2</td>
<td>0.9 ± 0.2</td>
</tr>
<tr>
<td>Patients with severe hypoglycemia (n, %)</td>
<td>8 (8%)</td>
<td>19 (10%)</td>
</tr>
<tr>
<td>Diabetic ketoacidosis (n, %)</td>
<td>0 (0)</td>
<td>1 (0.5%)</td>
</tr>
<tr>
<td>Baseline body weight (kg)</td>
<td>55.5 ± 19.0</td>
<td>54.1 ± 19.7</td>
</tr>
<tr>
<td>Weight Change from baseline (kg)</td>
<td>1.6 ± 2.1</td>
<td>1.8 ± 2.1</td>
</tr>
</tbody>
</table>

*a* Values are Mean ± SD  
*b* Severe hypoglycemia refers to hypoglycemia associated with central nervous system symptoms and requiring the intervention of another person or hospitalization.
16.1 How Supplied

HUMALOG 100 units per mL (U-100) is available as:

<table>
<thead>
<tr>
<th>Product Description</th>
<th>NDC Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mL vials</td>
<td>NDC 0002-7510-01 (VL-7510)</td>
</tr>
<tr>
<td>3 mL vials</td>
<td>NDC 0002-7510-17 (VL-7533)</td>
</tr>
<tr>
<td>5 x 3 mL cartridges</td>
<td>NDC 0002-7516-59 (VL-7516)</td>
</tr>
<tr>
<td>5 x 3 mL Humalog KwikPen (prefilled)</td>
<td>NDC 0002-8799-59 (HP-8799)</td>
</tr>
</tbody>
</table>

Each prefilled KwikPen, cartridge, and reusable pen compatible with Lilly 3 mL cartridges is for use by a single patient. Humalog KwikPens, cartridges, and reusable pens compatible with Lilly 3 mL cartridges must never be shared between patients, even if the needle is changed. Patients using Humalog vials must never share needles or syringes with another person.

16.2 Storage and Handling

Do not use after the expiration date.

Unopened HUMALOG should be stored in a refrigerator (36° to 46°F [2° to 8°C]), but not in the freezer. Do not use HUMALOG if it has been frozen. In-use HUMALOG vials, cartridges, and HUMALOG KwikPen should be stored at room temperature, below 86°F (30°C) and must be used within 28 days or be discarded, even if they still contain HUMALOG. Protect from direct heat and light. See table below:

<table>
<thead>
<tr>
<th></th>
<th>Not In-Use (Unopened) Room Temperature (Below 86°F [30°C])</th>
<th>Not In-Use (Unopened) Refrigerated</th>
<th>In-Use (Opened) Room Temperature, (Below 86°F [30°C])</th>
</tr>
</thead>
<tbody>
<tr>
<td>10 mL vial</td>
<td>28 days</td>
<td>Until expiration date</td>
<td>28 days, refrigerated/room temperature.</td>
</tr>
<tr>
<td>3 mL vial</td>
<td>28 days</td>
<td>Until expiration date</td>
<td>28 days, refrigerated/room temperature.</td>
</tr>
<tr>
<td>3 mL cartridge</td>
<td>28 days</td>
<td>Until expiration date</td>
<td>28 days, Do not refrigerate.</td>
</tr>
<tr>
<td>3 mL Humalog KwikPen (prefilled)</td>
<td>28 days</td>
<td>Until expiration date</td>
<td>28 days, Do not refrigerate.</td>
</tr>
</tbody>
</table>

Use in an External Insulin Pump — Change the HUMALOG in the reservoir at least every 7 days, change the infusion sets and the infusion set insertion site at least every 3 days or after exposure to temperatures that exceed 98.6°F (37°C). A HUMALOG 3 mL cartridge used in the D-Tron pumps should be discarded after 7 days, even if it still contains HUMALOG. However, as with other external insulin pumps, the infusion set should be replaced and a new infusion set insertion site should be selected at least every 3 days.

Diluted HUMALOG for Subcutaneous Injection — Diluted HUMALOG may remain in patient use for 28 days when stored at 41°F (5°C) and for 14 days when stored at 86°F (30°C). Do not dilute HUMALOG contained in a cartridge or HUMALOG used in an external insulin pump.

16.3 Preparation and Handling

Diluted HUMALOG for Subcutaneous Injection — HUMALOG may be diluted with Sterile Diluent for HUMALOG for subcutaneous injection. Diluting one part HUMALOG to nine parts diluent will yield a
concentration one-tenth that of HUMALOG (equivalent to U-10). Diluting one part HUMALOG to one part diluent will yield a concentration one-half that of HUMALOG (equivalent to U-50).

16.4 Admixture for Intravenous Administration
Infusion bags prepared with HUMALOG are stable when stored in a refrigerator (2°C to 8°C [36°F to 46°F]) for 48 hours and then may be used at room temperature for up to an additional 48 hours [see Dosage and Administration (2.4)].

17 PATIENT COUNSELING INFORMATION
See FDA-approved patient labeling (Patient Information and Instructions for Use).

17.1 Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 mL Cartridges, or Syringe Between Patients
Advise patients that they must never share a Humalog KwikPen, cartridge, or reusable pen compatible with Lilly 3 mL cartridges with another person, even if the needle is changed. Advise patients using Humalog vials not to share needles or syringes with another person. Sharing poses a risk for transmission of blood-borne pathogens.

17.2 Instructions for All Patients
Patients should be instructed on self-management procedures including glucose monitoring, proper injection technique, and management of hypoglycemia and hyperglycemia. Patients must be instructed on handling of special situations such as intercurrent conditions (illness, stress, or emotional disturbances), an inadequate or skipped insulin dose, inadvertent administration of an increased insulin dose, inadequate food intake, and skipped meals. Refer patients to the HUMALOG Patient Information Leaflet for additional information.

Women with diabetes should be advised to inform their doctor if they are pregnant or are contemplating pregnancy.

Accidental mix-ups between HUMALOG and other insulins have been reported. To avoid medication errors between HUMALOG and other insulins, patients should be instructed to always check the insulin label before each injection.

17.3 For Patients Using Continuous Subcutaneous Insulin Pumps
Patients using external pump infusion therapy should be trained appropriately.

The following insulin pumps have been tested in HUMALOG clinical trials conducted by Eli Lilly and Company.
- Disetronic® H-Tron® plus V100, D-Tron® and D-Tronplus® with Disetronic Rapid infusion sets
- MiniMed® Models 506, 507 and 508 and Polyfin® infusion sets

HUMALOG is recommended for use in pump systems suitable for insulin infusion such as MiniMed, Disetronic, and other equivalent pumps. Before using HUMALOG in a pump system, read the pump label to make sure the pump is indicated for continuous delivery of fast-acting insulin. HUMALOG is recommended for use in any reservoir and infusion sets that are compatible with insulin and the specific pump. Please see recommended reservoir and infusion sets in the pump manual.

To avoid insulin degradation, infusion set occlusion, and loss of the preservative (metacresol), insulin in the reservoir should be replaced at least every 7 days; infusion sets and infusion set insertion sites should be changed at least every 3 days.

Insulin exposed to temperatures higher than 98.6°F (37°C) should be discarded. The temperature of the insulin may exceed ambient temperature when the pump housing, cover, tubing or sport case is
exposed to sunlight or radiant heat. Infusion sites that are erythematous, pruritic, or thickened should be reported to the healthcare professional, and a new site selected because continued infusion may increase the skin reaction or alter the absorption of HUMALOG.

Pump or infusion set malfunctions or insulin degradation can lead to rapid hyperglycemia and ketosis. This is especially pertinent for rapid acting insulin analogs that are more rapidly absorbed through skin and have a shorter duration of action. Prompt identification and correction of the cause of hyperglycemia or ketosis is necessary. Problems include pump malfunction, infusion set occlusion, leakage, disconnection or kinking, and degraded insulin. Less commonly, hypoglycemia from pump malfunction may occur. If these problems cannot be promptly corrected, patients should resume therapy with subcutaneous insulin injection and contact their healthcare professionals. [See Dosage and Administration (2.3), Warnings and Precautions (5.8), and How Supplied/Storage and Handling (16)].

1 3 mL cartridge is for use in Eli Lilly and Company's HumaPen® Memoir™ and HumaPen® Luxura® HD insulin delivery devices, Owen Mumford, Ltd.'s Autopen® 3-mL insulin delivery device and Disetronic D-TRON® and D-TRON® Plus pumps.

Autopen® is a registered trademark of Owen Mumford, Ltd.
Humalog®, Humalog KwikPen®, HumaPen®, HumaPen® Memoir™, HumaPen® Luxura® and HumaPen® Luxura® HD are trademarks of Eli Lilly and Company.

2 Disetronic®, H-Tron®, D-Tron®, and D-Tronplus® are registered trademarks of Roche Diagnostics GmbH.

3 MiniMed® and Polyfin® are registered trademarks of MiniMed, Inc.

Other product and company names may be the trademarks of their respective owners.

Literature revised March 12, 2015

Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA

www.humalog.com

Copyright © 1996, 2015, Eli Lilly and Company. All rights reserved.

LOG-0001-USPI-20150312

Patient Information

HUMALOG® (HU-ma-log)
(insulin lispro injection, USP [rDNA origin]) for injection

What is HUMALOG?
• HUMALOG is a man-made fast-acting insulin used to control high blood sugar in adults and children with diabetes mellitus.
• It is not known if HUMALOG is safe and effective in children younger than 3 years of age or when used to treat children with type 2 diabetes mellitus.

Who should not use HUMALOG?

Do not use HUMALOG if you:
• are having an episode of low blood sugar (hypoglycemia).
• have an allergy to HUMALOG or any of the ingredients in HUMALOG.

Before using HUMALOG, tell your healthcare provider about all of your medical conditions, including if you:
• have kidney or liver problems.
• take any other medicines, especially ones commonly called TZDs (thiazolidinediones).
• have heart failure or other heart problems. If you have heart failure, it may get worse while you take TZDs with HUMALOG.
• **have any other medical conditions.** Some medical conditions can affect your insulin needs and your dose of HUMALOG.
• **are pregnant or plan to become pregnant.** Talk to your healthcare provider if you are pregnant or plan to become pregnant. You and your healthcare provider should decide about the best way to manage your diabetes while you are pregnant.
• **are breastfeeding or plan to breastfeed.** It is not known if HUMALOG passes into your breast milk. You and your healthcare provider should decide if you will use HUMALOG while you breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription or over-the-counter medicines, vitamins, or herbal supplements.

**Before you start using HUMALOG, talk to your healthcare provider about low blood sugar and how to manage it.**

**How should I use HUMALOG?**
• Read the Instructions for Use that come with your HUMALOG.
• **Do not share your Humalog KwikPen, cartridges, reusable pen compatible with Lilly 3 mL cartridges, or syringes with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.**
• Use HUMALOG exactly as your healthcare provider tells you to.
• **HUMALOG starts acting fast,** so inject it up to 15 minutes before or right after you eat a meal.
• Know the type and strength of insulin you use. **Do not** change the type of insulin you use unless your healthcare provider tells you to. The amount of insulin and the best time for you to take your insulin may need to change if you take a different type of insulin.
• **Check your blood sugar levels.** Ask your healthcare provider what your blood sugars should be and when you should check your blood sugar level.

**What should I avoid while using HUMALOG?**
**While using HUMALOG do not:**
• Drive or operate heavy machinery, until you know how HUMALOG affects you.
• Drink alcohol or use prescription or over-the-counter medicines that contain alcohol.

**What are the possible side effects of HUMALOG?**
**HUMALOG may cause serious side effects, including:**
• **low blood sugar (hypoglycemia).** Signs and symptoms that may indicate low blood sugar include:
  • dizziness or light-headedness, sweating, confusion, headache, blurred vision, slurred speech, shakiness, fast heartbeat, hunger, anxiety, irritability, or mood changes.

  **Your HUMALOG dose may need to change because of a:**
  • change in level of physical activity or exercise, weight gain or loss, change in diet, illness.
• **serious allergic reactions (whole body allergic reaction).** Get medical help right away, if you have any of these symptoms of an allergic reaction:
  • a rash over your whole body, trouble breathing, a fast heartbeat, sweating, feel faint.
• **low potassium in your blood (hypokalemia).**
• **heart failure.** Taking certain diabetes pills called thiazolidinediones or “TZDs” with HUMALOG may cause heart failure in some people. This can happen even if you have never had heart failure or heart problems before. If you already have heart failure it may get worse while you take TZDs with HUMALOG. Your healthcare provider should monitor you closely while you are taking TZDs with HUMALOG. Tell your healthcare provider if you have any new or worse symptoms of heart failure...
including:
- shortness of breath
- swelling of your ankles or feet
- sudden weight gain.

Treatment with TZDs and HUMALOG may need to be adjusted or stopped by your healthcare provider if you have new or worse heart failure.

**The most common side effects of HUMALOG include:**
- low blood sugar (hypoglycemia), reactions at the injection site, skin thickening or pits at the injection site (lipodystrophy), itching (pruritis), rash.

These are not all the possible side effects of HUMALOG.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**General information about the safe and effective use of HUMALOG.**
- Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or healthcare provider for information about HUMALOG that is written for health professionals.
- Do not use HUMALOG for a condition for which it was not prescribed. Do not give or share HUMALOG with other people, even if they also have diabetes. It may harm them.

**What are the ingredients in HUMALOG?**

**Active ingredient:** insulin lispro

**Inactive ingredients:** glycerin, dibasic sodium phosphate, metacresol, zinc oxide (zinc ion), trace amounts of phenol and water for injection

The brands listed are trademarks of their respective owners and are not trademarks of Eli Lilly and Company.

Humalog® and Humalog KwikPen® are registered trademarks of Eli Lilly and Company.

**Marketed by:** Lilly USA, LLC, Indianapolis, IN 46285, USA

For more information, go to www.humalog.com or call 1-800-545-5979.

This Patient Information has been approved by the U.S. Food and Drug Administration

Patient Information revised: March 13, 2015

Copyright © 1996, 2015, Eli Lilly and Company. All rights reserved.

LOG-0002-PPI-20150313

**Instructions for Use**

**HUMALOG® (HU-ma-log)**
(insulin lispro injection, USP [rDNA origin])
10 mL Vial (100 Units/mL, U-100)

Read the Instructions for Use before you start taking HUMALOG and each time you get a new HUMALOG vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

**Do not share your syringes with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.**

**Supplies needed to give your injection**
Preparing your HUMALOG dose

- Wash your hands with soap and water.
- Check the HUMALOG label to make sure you are taking the right type of insulin. This is especially important if you use more than 1 type of insulin.
- HUMALOG should look clear and colorless. **Do not** use HUMALOG if it is thick, cloudy, or colored, or if you see lumps or particles in it.
- **Do not** use HUMALOG past the expiration date printed on the label or 28 days after you first use it.
- **Always use a new syringe or needle for each injection to help ensure sterility and prevent blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.**

Step 1:
If you are using a new vial, pull off the plastic Protective Cap, but **do not** remove the Rubber Stopper.

**Step 2:**
Wipe the Rubber Stopper with an alcohol swab.

**Step 3:**
Hold the syringe with the needle pointing up. Pull down on the Plunger until the tip of the Plunger reaches the line for the number of units for your prescribed dose.

(Example Dose: 20 units shown)

**Step 4:**
Push the needle through the Rubber Stopper of the vial.

**Step 5:**
Push the Plunger all the way in. This puts air into the vial.

**Step 6:**
Turn the vial and syringe upside down and slowly pull the plunger down until the tip is a few units past the line for your prescribed dose.

If there are air bubbles, tap the syringe gently a few
times to let any air bubbles rise to the top.

Step 7:
Slowly push the plunger up until the tip reaches the line for your prescribed dose.
Check the syringe to make sure that you have the right dose.

Step 8:
Pull the syringe out of the vial's Rubber Stopper.

If you use HUMALOG with NPH insulin:
- NPH insulin is the only type of insulin that can be mixed with HUMALOG. Do not mix HUMALOG
with any other type of insulin.
- **HUMALOG** should be drawn up into the syringe first, before you draw up your NPH insulin. Talk to your healthcare provider if you are not sure about the right way to mix HUMALOG and NPH insulin.
- Give your injection right away.

**Giving your HUMALOG Injection with a syringe**
- Inject your insulin exactly as your healthcare provider has shown you.
- **HUMALOG starts acting fast,** so give your injection within 15 minutes before or right after you eat a meal.
- **Change (rotate) your injection site** for each injection.

**Step 9:**
Choose your injection site. HUMALOG is injected under the skin (subcutaneously) of your stomach area (abdomen), buttocks, upper legs or upper arms. Wipe the skin with an alcohol swab. Let the injection site dry before you inject your dose.

**Step 10:**
Insert the needle into your skin.
Step 11:
Push down on the Plunger to inject your dose. The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your insulin dose.

Step 12:
Pull the needle out of your skin.
- You may see a drop of insulin at the needle tip. This is normal and does not affect the dose you just received.
- If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. Do not rub the area.
- Do not recap the needle. Recapping the needle can lead to a needle stick injury.

Giving your HUMALOG using an insulin pump
- Change your insertion site every 3 days.
- Change the insulin in the reservoir at least every 7 days, even if you have not used all of the insulin.
- Do not dilute or mix HUMALOG with any other type of insulin in your insulin pump.
- See your insulin pump manual for instructions or talk to your healthcare provider.

Disposing of used needles and syringes
- Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash.
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  - made of a heavy-duty plastic,
  - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  - upright and stable during use,
  - leak-resistant, and
  - properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or
local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.

- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

How should I store HUMALOG?

All unopened HUMALOG vials:
- Store all unopened vials in the refrigerator.
- Do not freeze. Do not use if it has been frozen.
- Keep away from heat and out of direct light.
- Unopened vials can be used until the expiration date on the carton and label, if they have been stored in the refrigerator.
- Unopened vials should be thrown away after 28 days, if they are stored at room temperature.

After HUMALOG vials have been opened:
- Store opened vials in the refrigerator or at room temperature below 86°F (30°C) for up to 28 days.
- Keep vials away from heat and out of direct light.
- Throw away all opened vials after 28 days of use, even if there is insulin left in the vial.

General information about the safe and effective use of HUMALOG
- Keep HUMALOG vials, syringes, needles, and all medicines out of the reach of children.
- Always use a new syringe or needle for each injection.
- Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.

If you have any questions or problems with your HUMALOG, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help. For more information on HUMALOG and insulin, go to www.humalog.com.

Scan this code to launch the humalog.com website

These Instructions for Use have been approved by the U.S. Food and Drug Administration.
Humalog® is a registered trademarks of Eli Lilly and Company.
Instructions for Use issued: March 13, 2015

Marketed by: Lilly USA, LLC, Indianapolis, IN 46285, USA
Copyright © 1996, 2015, Eli Lilly and Company. All rights reserved.
LOGVL-0001-IFU-20150313

Instructions for Use

HUMALOG KwikPen®
insulin lispro injection (rDNA origin)
Read the Instructions for Use before you start taking HUMALOG and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.

**Do not share your HUMALOG KwikPen with other people, even if the needle has been changed. You may give other people a serious infection or get a serious infection from them.**

HUMALOG KwikPen® (“Pen”) is a disposable pen containing 3 mL (300 units) of U-100 HUMALOG® [insulin lispro injection (rDNA origin)] insulin. You can inject from 1 to 60 units in a single injection.

This Pen is not recommended for use by the blind or visually impaired without the assistance of a person trained in the proper use of the product.

**Supplies you will need to give your HUMALOG injection:**
- HUMALOG KwikPen
- HUMALOG KwikPen compatible needle (Becton, Dickinson and Company Pen Needles recommended)
- Alcohol swab

**Preparing HUMALOG KwikPen:**
- Wash your hands with soap and water.
- Check the HUMALOG KwikPen Label to make sure you are taking the right type of insulin. This is
especially important if you use more than 1 type of insulin.

- Do not use HUMALOG past the expiration date printed on the Label.
- Always use a new needle for each injection to help ensure sterility and prevent blocked needles. Do not reuse or share your needles with other people. You may give other people a serious infection or get a serious infection from them.

Step 1:
Pull the Pen Cap straight off.

Wipe the Rubber Seal with an alcohol swab.

- Do not twist the cap.
- Do not remove the KwikPen Label.

HUMALOG should look clear and colorless. Do not use HUMALOG if it is thick, cloudy, colored, has solid particles or clumps in it.

Step 2:
Pull off the Paper Tab from Outer Needle Shield.

Step 3:
Push the capped Needle straight onto the Pen and turn the Needle forward until it is tight.

Step 4:
Pull off the Outer Needle Shield. Do not throw it away.

Pull off the Inner Needle Shield and throw it away.

Priming your HUMALOG KwikPen:
Prime before each injection. Priming ensures the Pen is ready to dose and removes air that may collect in the cartridge during normal use. If you do not prime before each injection, you may get too much or too little insulin.

**Step 5:**
Turn the Dose Knob to select 2 units.

**Step 6:**
Hold your Pen with the Needle pointing up. Tap the Cartridge Holder gently to collect air bubbles at the top.

**Step 7:**
Hold your Pen with Needle pointing up. Push the Dose Knob in until it stops, and “0” is seen in the Dose Window. Hold the Dose Knob in and count to 5 slowly.

- A stream of insulin should be seen from the needle.
  - If you do not see a stream of insulin, repeat steps 5 to 7, no more than 4 times.
  - If you still do not see a stream of insulin, change the needle and repeat steps 5 to 7.

**Selecting your dose:**

**Step 8:**
Turn the Dose Knob to select the number of units you need to inject. The Dose Indicator should line up with your dose.

- The dose can be corrected by turning the Dose Knob in either direction until the correct dose lines up with the Dose Indicator.
- The **even** numbers are printed on the dial. The **odd** numbers, after the number 1, are shown as full lines.

The HUMALOG KwikPen will not let you dial more than the number of units left in the Pen.

If your dose is more than the number of units left in the Pen, you may either:

- inject the amount left in your Pen and then use a new Pen to give the rest of your dose, **or**
- get a new Pen and inject the full dose.

- The Pen is designed to deliver a total of 300 units of insulin. The cartridge contains an additional small amount of insulin that can't be delivered.

**Giving your HUMALOG injection:**
- Inject your HUMALOG as your healthcare provider has shown you.
- Change (rotate) your injection site for each injection.
- **Do not** try to change your dose while injecting HUMALOG.

**Step 9:**
Choose your injection site.

HUMALOG is injected under the skin (subcutaneously) of your stomach area, buttocks, upper legs or upper arms.

Wipe the skin with an alcohol swab, and let the injection site dry before you inject your dose.

**Step 10:**
Insert the Needle into your skin.

**Step 11:**
Put your thumb on the Dose Knob and push the Dose Knob in until it stops. Hold the Dose Knob in and **slowly count to 5**.

**Step 12:**
Pull the Needle out of your skin.

You should see “0” in the Dose Window. If you do not see “0” in the Dose Window, you did not receive your full dose.

If you see blood after you take the Needle out of your skin, press the injection site lightly with a piece of gauze or an alcohol swab. **Do not** rub the area.
A drop of insulin at the needle tip is normal. It will not affect your dose.

**If you do not think you received your full dose, do not take another dose.** Call Lilly or your healthcare provider for assistance.

<table>
<thead>
<tr>
<th>Step 13:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carefully replace the Outer Needle Shield.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 14:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unscrew the capped Needle and throw it away.</td>
</tr>
<tr>
<td>Do not store the Pen with the Needle attached to prevent leaking, blocking of the Needle, and air from entering the Pen.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Step 15:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Replace the Pen Cap by lining up the Cap Clip with the Dose Indicator and pushing straight on.</td>
</tr>
</tbody>
</table>

**After your injection:**
- Put your used needles in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles in your household trash.
- If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  - made of a heavy-duty plastic,
  - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  - upright and stable during use,
  - leak-resistant, and
  - properly labeled to warn of hazardous waste inside the container.
- When your sharps disposal container is almost full, you will need to follow your community
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal

- Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
- The used Pen may be discarded in your household trash after you have removed the needle.

**How should I store my HUMALOG KwikPen?**

- Store unused HUMALOG Pens in the refrigerator at 36°F to 46°F (2°C to 8°C). The Pen you are currently using can be stored out of the refrigerator below 86°F (30°C).
- **Do not freeze HUMALOG. Do not use HUMALOG if it has been frozen.**
- Unused HUMALOG Pens may be used until the expiration date printed on the Label, if kept in the refrigerator.
- The HUMALOG Pen you are using should be thrown away after 28 days, even if it still has insulin left in it.
- Keep HUMALOG away from heat and out of the light.

**General information about the safe and effective use of HUMALOG KwikPen**

- **Keep HUMALOG KwikPen and needles out of the reach of children.**
- **Always** use a new needle for each injection.
- **Do not share your Pen or needles with other people. You may give other people a serious infection or get a serious infection from them.**
- **Do not** use your Pen if any part looks broken or damaged.
- Always carry an extra Pen in case yours is lost or damaged.
- If you can not remove the Pen Cap, gently twist the Pen Cap back and forth, and then pull the Pen Cap straight off.
- If it is hard to push the Dose Knob or the Pen is not working the right way:
  - Your Needle may be blocked. Put on a new Needle and prime the Pen.
  - You may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new one.
  - It may help to push the Dose Knob more slowly during your injection.

- Use the space below to keep track of how long you should use each HUMALOG KwikPen.
  - Write down the date you start using your HUMALOG KwikPen. Count forward 28 days.
  - Write down the date you should throw it away.

**Example:**

Pen 1 - First used on _______ + 28 days = Throw out on _______

<table>
<thead>
<tr>
<th>Date</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pen 1 - First used on _______</td>
<td>Throw out on _______</td>
</tr>
<tr>
<td>Date</td>
<td>Date</td>
</tr>
<tr>
<td>Pen 2 - First used on _______</td>
<td>Throw out on _______</td>
</tr>
<tr>
<td>Date</td>
<td>Date</td>
</tr>
<tr>
<td>Pen 3 - First used on _______</td>
<td>Throw out on _______</td>
</tr>
<tr>
<td>Date</td>
<td>Date</td>
</tr>
<tr>
<td>Pen 4 - First used on _______</td>
<td>Throw out on _______</td>
</tr>
</tbody>
</table>

Your Needle may be blocked. Put on a new Needle and prime the Pen.
You may have dust, food, or liquid inside the Pen. Throw the Pen away and get a new one.
It may help to push the Dose Knob more slowly during your injection.

- Write down the date you start using your HUMALOG KwikPen. Count forward 28 days.
- Write down the date you should throw it away.
Pen 5 - First used on _______  Throw out on ______

If you have any questions or problems with your HUMALOG KwikPen, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help. For more information on HUMALOG KwikPen and insulin, go to www.humalog.com.

These Instructions for Use have been approved by the U.S. Food and Drug Administration.

Humalog® and Humalog KwikPen® are trademarks of Eli Lilly and Company.

Revised: March 13, 2015

Marketed by: Lilly USA, LLC
Indianapolis, IN 46285, USA

Copyright © 2007, 2015, Eli Lilly and Company. All rights reserved.

Humalog KwikPen meets the current dose accuracy and functional requirements of ISO 11608-1:2000.

LOGKP-0002-IFU-20150313

PACKAGE CARTON – HUMALOG 10 mL vial
NDC 0002-7510-01
10 mL
VL-7510
100 units per mL
Humalog®
insulin lispro injection, USP
(rDNA origin)
Rx only
U-100
humalog.com
Lilly
PACKAGE CARTON – HUMALOG KwikPen

NDC 0002-8799-59
Humalog KwikPen®
insulin lispro injection, USP (rDNA origin)
For Single Patient Use Only
HP-8799
U-100
Rx only
100 units per mL
Needles not included
This device is recommended for use with Becton, Dickinson and Company's insulin pen needles prefilled insulin delivery device
5 x 3 mL Prefilled Pens
Read Insulin Delivery Device Instructions for Use
PACKAGE CARTON – HUMALOG Cartridge 3mL

NDC 0002-7516-59
100 units per mL
VL-7516
5 x 3 mL Cartridges
Humalog®
insulin lispro injection, USP (rDNA origin)
For Single Patient Use Only
Rx only
U-100
For use in Eli Lilly and Company's HumaPen MEMOIR™
and HumaPen® LUXURA™ HD insulin delivery devices
and Owen Mumford, Ltd.'s Autopen® 3 mL insulin delivery device.
HUMALOG
insulin lispro injection, solution

<table>
<thead>
<tr>
<th>Product Information</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Product Type</strong></td>
</tr>
<tr>
<td><strong>Route of Administration</strong></td>
</tr>
<tr>
<td><strong>Item Code (Source)</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Active Ingredient/Active Moiety</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ingredient Name</strong></td>
</tr>
<tr>
<td>Insulin lispro (UNII: GFX7QISII) (Insulin lispro - UNII:GFX7QISII)</td>
</tr>
</tbody>
</table>

| Inactive Ingredients |
### Ingredient Name

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerin (UNII: PDC6A3C0OX)</td>
<td>16 mg in 1 mL</td>
</tr>
<tr>
<td>Sodium Phosphate, Dibasic (UNII: GR686LBA74)</td>
<td>1.88 mg in 1 mL</td>
</tr>
<tr>
<td>Metacresol (UNII: GGO4Y809LO)</td>
<td>3.15 mg in 1 mL</td>
</tr>
<tr>
<td>Zinc (UNII: J41CSQ7QDS)</td>
<td>.0197 mg in 1 mL</td>
</tr>
<tr>
<td>Phenol (UNII: 339NCG44TV)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>Hydrochloric acid (UNII: QTT17582CB)</td>
<td></td>
</tr>
<tr>
<td>Sodium hydroxide (UNII: 55X04QC32I)</td>
<td></td>
</tr>
</tbody>
</table>

### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0002-7510-01</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:0002-7510-17</td>
<td>10 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0002-7510-01</td>
<td>1 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0002-7510-99</td>
<td>3 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>NDC:0002-7510-99</td>
<td>10 mL in 1 VIAL; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA020563</td>
<td>07/24/1996</td>
<td></td>
</tr>
</tbody>
</table>

## HUMALOG KWIKPEN

**insulin lispro injection, solution**

### Product Information

<table>
<thead>
<tr>
<th>Product Type</th>
<th>HUMAN PRESCRIPTION DRUG</th>
<th>Item Code (Source)</th>
<th>NDC:0002-8799</th>
</tr>
</thead>
<tbody>
<tr>
<td>Route of Administration</td>
<td>INTRAVENOUS, SUBCUTANEOUS</td>
<td>DEA Schedule</td>
<td></td>
</tr>
</tbody>
</table>

### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin lispro (UNII: GFX7QISIII) (Insulin lispro - UNII:GFX7QISIII)</td>
<td>Insulin lispro</td>
<td>100 [iU] in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerin (UNII: PDC6A3C0OX)</td>
<td>16 mg in 1 mL</td>
</tr>
<tr>
<td>Sodium Phosphate, Dibasic (UNII: GR686LBA74)</td>
<td>1.88 mg in 1 mL</td>
</tr>
<tr>
<td>Metacresol (UNII: GGO4Y809LO)</td>
<td>3.15 mg in 1 mL</td>
</tr>
<tr>
<td>Zinc (UNII: J41CSQ7QDS)</td>
<td>.0197 mg in 1 mL</td>
</tr>
</tbody>
</table>
### Active Ingredient/Active Moiety

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Basis of Strength</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin lispro (UNII: GFX7QIS1II) (Insulin lispro - UNII:GFX7QIS1II)</td>
<td>Insulin lispro</td>
<td>100 [iU] in 1 mL</td>
</tr>
</tbody>
</table>

### Inactive Ingredients

<table>
<thead>
<tr>
<th>Ingredient Name</th>
<th>Strength</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerin (UNII: PDC6A3C0OX)</td>
<td>16 mg in 1 mL</td>
</tr>
<tr>
<td>Sodium Phosphate, Dibasic (UNII: GR686LBA74)</td>
<td>1.88 mg in 1 mL</td>
</tr>
<tr>
<td>Metacresol (UNII: GGO4Y809LO)</td>
<td>3.15 mg in 1 mL</td>
</tr>
<tr>
<td>Zinc (UNII: J41CSQ7QDS)</td>
<td>.0197 mg in 1 mL</td>
</tr>
<tr>
<td>Phenol (UNII: 339NCG44TV)</td>
<td></td>
</tr>
<tr>
<td>Water (UNII: 059QF0KO0R)</td>
<td></td>
</tr>
<tr>
<td>Hydrochloric acid (UNII: QTT17582CB)</td>
<td></td>
</tr>
<tr>
<td>Sodium hydroxide (UNII: 55X04QC32I)</td>
<td></td>
</tr>
</tbody>
</table>
### Packaging

<table>
<thead>
<tr>
<th>#</th>
<th>Item Code</th>
<th>Package Description</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NDC:0002-7516-59</td>
<td>5 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>NDC:0002-7516-01</td>
<td>3 mL in 1 CARTRIDGE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0002-7516-99</td>
<td>5 in 1 CARTON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>NDC:0002-7516-99</td>
<td>3 mL in 1 CARTRIDGE; Type 0: Not a Combination Product</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Marketing Information

<table>
<thead>
<tr>
<th>Marketing Category</th>
<th>Application Number or Monograph Citation</th>
<th>Marketing Start Date</th>
<th>Marketing End Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA</td>
<td>NDA020563</td>
<td>02/20/1998</td>
<td></td>
</tr>
</tbody>
</table>

**Labeler** - Eli Lilly and Company (006421325)

Revised: 3/2015